Antibiotics and probiotics in inflammatory bowel disease: Why, when, and how

Current Opinion in Gastroenterology

Volumn 25, Issue 4, 2009, Pages 329-333

  Prantera, Cosimo ^a   Scribano, Maria Lia ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Antibiotics; Crohn's disease; Inflammatory bowel disease; Intestinal bacteria; Probiotics; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIMYCOBACTERIAL AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; MESALAZINE; METRONIDAZOLE; ORNIDAZOLE; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAXIMIN; STEROID;

ACUTE DIARRHEA; ADD ON THERAPY; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; CAPSULE ENDOSCOPY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COLON CROHN DISEASE; CROHN DISEASE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ENTERITIS; ESCHERICHIA COLI; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FLORA; MYCOBACTERIUM PARATUBERCULOSIS; PATHOGENESIS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; PROBIOTICS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 68049093112     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832b20bf     Document Type: Review

References (41)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
2. Sartour RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126:1620-1633
3. Prantera C. What role do antibiotics have in the treatment of IBD? Nat Clin Pract Gastroenterol Hepatol 2008; 5:670-671.
4. Chiodini RJ, Van Kruiningen HJ, Thajer WR, et al. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984; 29:1073-1079.
5. Graham DY, Markesich DC, Yoshimura HH. Mycobacteria as the cause of Crohn's disease. Gastroenterology 1989; 97:1354-1356
6. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95:725-729. (Pubitemid 30123910)
7. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132:2313-2319. (Pubitemid 46890859)
8. Peyrin-Biroulet L, Neut C, Colombel J-F. Antimycobacterial therapy in Crohn's disease: game over? Gastroenterology 2007; 132:2594-2598.
9. Lipton JE, Barash DP. Flawed Australian CD study does not end MAP controversy. Gastroenterology 2007; 133:1742.
10. Kuenstner JT. The Australian antibiotic trial in Crohn's disease: alternative conclusions from the same study. Gastroenterology 2007; 133:1742-1743.
11. Gitlin L, Biesecker J. Australian Crohn's antibiotic study opens new horizons. Gastroenterology 2007; 133:1743-1744. (Pubitemid 350029759)
12. Chamberlin W. Importance of the Australian Crohn's disease antibiotic study. Gastroenterology 2007; 133:1744-1745. (Pubitemid 350029758)
13. Prantera C. Mycobacteria and Crohn's disease. The endless story. Dig Liver Dis 2007; 39:452-454.
14. Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 2007; 23:16-20. (Pubitemid 44875904)
15. Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut 2007; 56:610-612. (Pubitemid 46662923)
16. Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest 2007; 87:1042-1054. (Pubitemid 47429187)
17. Leiper K, Martin K, Ellis A, et al. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27:1233-1239. Clarithromycin is not effective in inducing response or remission in 41 patients with Crohn's disease with signs of bacterial activity shown by CRP elevated value. (Pubitemid 351697272)
18. D'Haens G, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135:1123-1129 The combination of azathioprine given for 1 year with 3 months of metronidazole is able to reduce the endoscopic recurrence in patients with high risk of lesion recurrence after surgery.
19. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6:1105-1111. The complications of Crohn's disease in children are highly correlated with elevated antibodies to microbial antigens.
20. Shafran I, Burgunder P. Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. Am J Gastroenterol 2008; 103:2158-2160.
21. Doman DB, Goldberg HJ, Golding MI. 'Ecologic niche' therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q maintenance therapy. Am J Gastroenterol 2008; 103:251-252.
22. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double-blind, randomized, placebocontrolled trial with rifaximin. Aliment Pharmacol Ther 2006; 23:1117-1125. (Pubitemid 43779351)
23. Angelberger S, Reinisch W, Dejaco C, et al. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am J Gastroenterol 2008; 103:1197-1202. Perianal disease responds better to ciprofloxacin in patients with NOD2/CARD15 wild type compared with those with NOD2/CARD15 variants. (Pubitemid 351677965)
24. Swidsinski A, Loening-Baucke V, Bengmark S, et al. Bacterial biofilm suppression with antibiotics for ulcerative and indeterminate colitis: consequences of aggressive treatment. Arch Med Res 2008; 39:198-204. This important article describes the rebound effect of the suppression of mucosal flora induced after stopping the antibiotics.
25. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008; 2:24-62. The article reports the consensus of a group of European experts on the management of ulcerative colitis. (Pubitemid 351179488)
26. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007; 52:2920-2925. (Pubitemid 47512546)
27. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:339-344. (Pubitemid 46401530)
28. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:345-351. (Pubitemid 46401531)
29. Ananthakrishan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57:205-210. Patients with both IBD and Clostridium difficile infection carry a higher mortality than patients with infection without IBD.
30. Stone CD. Prognosis in Clostridium difficile infection complicating inflammatory bowel disease. Gut 2008; 57:150-152. The editorial comment highlights the growing problem of Clostridium difficile infection in general population and, in particular, in IBD patients.
31. Bartlett JG, Perl TM. The new Clostridium difficile: what does it mean? N Engl J Med 2005; 353:2503-2505.
32. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95:S2-S4.
33. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:1046-1049 (Pubitemid 24310035)
34. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96:981-988.
35. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006; 18:CD:004826.
36. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53:2524-2531.
37. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 16:CD:006634.
38. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 17:CD:005573.
39. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
40. Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med 2007; 65:411-418.
41. Prantera C. Probiotics for Crohn's disease: what have we learned? Gut 2006; 55:757-759.